INDEPENDENT OPINION & ANALYSISSTATE & NATION PERSPECTIVE EDITORIAL
THE GOVERNMENT NEWS DESK
All U.S. Senate editorials
U.S. Senate / OPINION

Opinion: The FTC's PBM Study Needs a Final Evidence-Based Conclusion

Sens. Chuck Grassley and Maria Cantwell urged the FTC to complete a pharmacy-benefit-manager study opened in 2022 and give Congress final recommendations on competition and consumer protection.

OUR POSITION

A final report is overdue and should distinguish documented conduct from market-wide inference, quantify effects on patients, employers and pharmacies, and identify which problems existing law can remedy before Congress adds new requirements.

What the release says

The bipartisan letter asks the Federal Trade Commission to finish and publish its Section 6(b) study of pharmacy benefit managers, begun in June 2022.

The FTC issued interim staff reports in July 2024 and January 2025 but has not released a final study or comprehensive recommendations.

Grassley and Cantwell say the interim work raises concerns about concentration, vertical integration, drug steering, cost and transparency.

The letter is a congressional request; it does not itself establish a violation or impose a new rule.

Read the official release: Grassley, Cantwell Urge FTC to Finish Investigation into Pharmacy Benefit Managers' Practices, Provide Final Recommendations to Congress
EDITORIAL ANALYSIS

Our centrist perspective

A completed record would help Congress separate practices that reduce costs from those that shift revenue or restrict patient and pharmacy choice.

Delay leaves lawmakers, plan sponsors and patients debating policy without a final agency synthesis of the evidence already collected.

The tradeoffs

PBMs can negotiate discounts and administer complex benefits, while opaque rebates, ownership ties and steering incentives can make the distribution of savings difficult to evaluate.

New disclosure or competition rules may improve accountability but should avoid raising administrative costs without lowering net spending or improving access.

What to watch next

  • Watch whether the FTC sets a public completion date and releases methods, underlying data limitations and final recommendations.
  • Watch how any proposed legislation distinguishes gross prices, rebates, net plan costs, patient out-of-pocket costs and pharmacy reimbursement.

This is an editorial interpretation, not an official agency statement. Factual summaries rely on the linked release; implications and recommendations are our opinion. How we work

The State & NationCentrist. Nonpartisan. Evidence first.

Independent commentary with links to official sources.

Media KitInstall app
Property of State and Nation Media Group LLC.